RxDoctor Payments Data

Edward Paraiso

Urology · Trumbull, CTNPI 1740212141

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Procept Biorobotics Corporation at 26.8% of the total. Reporting peaked in 2019 at $2,478 and has fallen 89.0% since, to $272 in 2023.

$4,045in general payments, 2019–2025

Across 101 payments — averaging $40.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Neotract Inc.$921
  • Astellas Pharma US Inc$388
  • Coloplast$345
  • Pfizer$209
  • Johnson & Johnson$156
  • plus $944 from 18 others

What the payments were for

  • Travel & lodging$1,45336%
  • Food & beverage$1,88447%
  • Education$70817%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,045 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$354,405
Medicare patients
700
Services billed
42,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron352$393,831
XtandiEnzalutamide24$346,902
MyrbetriqMirabegron243$210,464
Tamsulosin Hcl981$13,817
Alfuzosin Hcl ErAlfuzosin Hcl677$13,709
ElmironPentosan Polysulfate Sodium11$11,211
Mirabegron ErMirabegron11$7,884
Fesoterodine Fumarate ErFesoterodine Fumarate61$7,450
Solifenacin Succinate206$7,047
Dutasteride200$6,751
Tolterodine Tartrate ErTolterodine Tartrate55$6,518
Finasteride428$6,080
Trospium Chloride ErTrospium Chloride44$5,957
Potassium Citrate ErPotassium Citrate74$5,665
Darifenacin ErDarifenacin Hydrobromide23$4,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$388$557,366267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 156 urology providers in Connecticut.

Other urology in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →